Aliada Therapeutics

📍 Boston, United States🗓 Founded 2021👥 23 employees💰 Last funded Dec 2022
Biotechnology🌐 aliadatx.com
Website LinkedIn
Biologics are transforming the treatment of numerous diseases, but many CNS diseases remain largely out of reach due to the challenge of crossing the blood-brain barrier and navigating the brain’s unique immune environment. Aliada is redefining what is possible in CNS drug development by building on a highly versatile and differentiated platform, with demonstrated proof of concept in NHPs. We are expanding this platform across a wide range of modalities, including monoclonal antibodies, enzymes, oligonucleotides, peptides, and other proteins. The delivery technology is customizable to CNS tissue and target localization via novel approaches to binding two distinct transport targets on the blood-brain barrier. In addition to the platform, Aliada is applying its novel technology to specific CNS target antibody binders and progressing these programs through preclinical evaluation.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2021
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Aliada Therapeutics?
Aliada Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Aliada Therapeutics last raise funding?
The most recent investment in Aliada Therapeutics recorded on gritt.io was in December 2022.
When was Aliada Therapeutics founded?
Aliada Therapeutics was founded in 2021.
What industry is Aliada Therapeutics in?
Aliada Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Aliada Therapeutics based?
Aliada Therapeutics is headquartered in Boston, United States.